top of page
Search
  • Writer's pictureFutureMeds

Introducing FutureMeds @home: the New European DCT Solution

With the aim of increasing DCT adoption, boosting trial effectiveness and driving better outcomes, FutureMeds, Europe's 1st Independent Dedicated DCT Site Network, has unveiled a new European DCT solution: FutureMeds @home.


Sponsors, CROs and industry partners can now access FutureMeds @home, a dedicated decentralised clinical trial solution that has been developed and streamlined over 10 years with trial efficiency, outcomes, quality, timeline protection and patient experience in mind. The solution integrates 'site and patient voice', and combines deep PI and site insights, novel trial design experience, proprietary homecare solutions, and streamlined operations.


"We're excited to drive meaningful momentum and results for our clients and patients. Speeding up the DCT adaptation process across the clinical trial industry in Europe can boost pharmaceutical R&D productivity, support and influence commercialisation strategies, and significantly enhance the patient experience, engagement and outcomes."

- Dr Radoslaw Janiak, CEO at FutureMeds


Sponsors, CROs and industry partners can extend their trials’ reach, boost recruitment and retention, access more diverse patient populations and improve trial outcomes through FutureMeds @home.

With the acquisition of emovis, the Berlin-based, dedicated study site and award-winning pan-European homecare visits and DCT solution provider, FutureMeds gained an incredible advantage and asset. Besides expediting the site network’s evolution, emovis experienced DCT and HomeCare visits teams fast-tracked product development.


As a result of close collaboration between our teams, partners and clients, can now leverage a new European DCT solution to

  • Extend trials' reach,

  • Boost recruitment and retention,

  • Access larger patient pools and more diverse patient populations

  • Improve trial outcomes and data

  • Protect timelines


“FutureMeds @home represents an important step forward for the European market. Besides enhancing and expanding DCT approaches across the continent, our goal is to increase patient participation in clinical research, improve their experience, boost retention and accelerate R&D timelines. This solution is a win-win-win for clients, patients and research professionals.”

- Iwona Tongbhoyai, Chief Client Solutions Officer at FutureMeds



FutureMeds @home - What’s under the hood


With over a decade of refinement of the DCT and Mobile HomeHealth elements of the solution, FutureMeds @home is developed with timeline protection in mind, ensuring that trials stay on track, outcomes are optimised, and quality is never compromised.


Successful trials boil down to

  • Sites, PI’s and patient engagement,

  • trust between participant & investigator,

  • protocols that consider the particularities of the therapeutic area and patient population, and

  • sound & efficient delivery.


To cater for each above vital aspects of successful trial delivery, we built FutureMeds @home around 3 core pillars:

  • DCT Framework & Toolkit

  • Proprietary Mobile HomeHealth

  • Novel Trial Design Consultancy


DCT Framework & Toolkit - The foundation


As a site network focusing solely on trials, we understand the complexities of delivering trials and how challenging it can be to customise the journey. That’s why we developed a toolkit that can reliably, and repeatably add clarity and efficiency to trial delivery, layer by layer, module by module.


By using FutureMeds @home’s DCT Framework & Toolkit, clients let it be CROs, Sponsors, and other industry providers, can personalise and customise their volunteers’ clinical trial journey, and boost patient recruitment & retention without increasing complexity or losing control, data quality or efficiency.


Our DCT Framework & Toolkit is a scalable non-fragmented, single-vendor foundation for any clinical trial. It is the streamlined service side of the puzzle that complements clients’ tech suite.


Keep control of delivery through 1 vendor and add clarity to your trial delivery, layer by layer, module by module.

Proprietary Mobile HomeHealth


Compared to the solutions that cropped up during or shortly after the pandemic in the wake of the rising DCT demand, FutureMeds’ Mobile HomeHealth has been evolved and optimised by emovis by FutureMeds over more than a decade.


Each part of the Mobile HomeHealth service has been put to the test, and each process has been thoroughly evaluated and optimised so we can

  • Deliver results repeatedly at a scale

  • Help clients keep control (1 vendor - no subcontractors involved)

  • Protect data quality and efficiency

  • Streamline the process flows and reduce the complexity.


Our solution is now present in 18 European countries, and our clients can access over 1,100+ vetted and clinical trial-trained nurses who understand PI challenges.


Our proprietary Mobile HomeHealth solution, paired with streamlined operations, can boost the reach and retention of most trials site-mix whilst ensuring that patients receive the best care, enhancing their overall trial experience and engagement.


Novel Trial Design Consultancy


By leveraging deep PI and site insights, local regulatory insights and study startup accelerating strategies, clients can finetune their trial protocols to support robust commercialisation plans.


Leverage deep PI and site insights, local regulatory insights and study startup accelerating solutions to inform, amend and finetune trial protocols that can support robust commercialisation plans.

We strongly believe in study delivery that is empowered by highly executable trial design and protocol. However, designing highly executable protocols, in most cases, is impossible without real-world data and investigator insights.


By working closely with sponsors and CROs, we have rescued studies by recommending DCT elements and protocol amendments that resulted in accelerated trial delivery and months of delays saved.


Our sites have screened hundreds of thousands of patients and consulted and worked with tens of thousands of them across hundreds of trials, and indications.


Due to the vast amount of insight, experience and successful study delivery track record of our investigators and teams, we can

  • Anticipate and identify problems that can delay or derail studies,

  • Provide trial and patient population-specific solutions

  • Boost collaboration between stakeholders and players of the value chain



The next logical step in Decentralised Clinical Trials


As we appreciate that there’s no one-size-fits-all DCT solution, and service elements need to be tailored to the trial, our FutureMeds @home is backed by robust site infrastructure with high traditional trial and DCT readiness.


By consulting our experts, clients can tap into the insights patient & country insights, weigh up opportunities, assess anticipated risks associated with the implementation of decentralised elements in the protocol and how those should be mitigated and pick elements that make the most sense from a trial outcome perspective.


FutureMeds @home is now available to Sponsors, CROs and industry partners. It is a dedicated decentralised clinical trial solution that has been developed and streamlined over 10 years with trial efficiency, outcomes, quality, timeline protection and patient experience in mind.


The solution integrates 'site and patient voice', and combines deep PI and site insights, novel trial design experience, proprietary homecare solutions, and streamlined operations.


Interested to learn more about FutureMeds @home? Visit our page or contact Iwona Tongbhoyai or Nicole Bohrmann to get an overview of how this solution can help future-proof trials in Europe.



About FutureMeds


FutureMeds is the 1st European Independent Dedicated DCT Site Network, offering high traditional trial and DCT readiness across the whole network and home nursing solutions in 18 countries.


FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help speed up drug development and patient access to new treatments.


Through acquisitions and a strategic focus on patient experience, FutureMeds has developed large, qualified patient pools across Europe that enable faster patient enrolment, stronger retention and more accurate results.


Follow us on LinkedIn


Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.


Comments


Commenting has been turned off.
bottom of page